Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Seragon

- PMLiVE

NICE backs GSK’s Tafinlar for skin cancer

Joins Yervoy and Zelboraf as a recommended melanoma treatment

- PMLiVE

Pressure put on Roche to cut Kadcyla’s UK price

30,000 people sign petition to help make the breast cancer drug available on the NHS

Roche - Basel

Strong sales in breast cancer lift Roche revenues

New products Perjeta and Kadcyla lead growth

- PMLiVE

Eisai launches online breast cancer resource

Website includes information on the disease, treatment options and side effects

- PMLiVE

Pfizer’s palbociclib on track for early 2015 launch

Good news for the highly anticipated breast cancer drug

- PMLiVE

Roche appoints Philip Atkinson to new global role

He will lead the company's new scientific communications group

- PMLiVE

Breast cancer drug market set to double in 10 years

New entrants will join market leaders Roche, Novartis and AstraZeneca

- PMLiVE

PD1 drugs could end ‘decades of silence’ in bladder cancer therapy

Merck's Keytruda and Roche antibody showing promise

- PMLiVE

Janssen, AZ and Roche at ESMO

Companies present promising data on new cancer drugs

Roche's Perjeta pertuzumab

Roche’s Perjeta should be ‘new standard’ in breast cancer

Could improve survival when added to therapy with Herceptin and docetaxel

- PMLiVE

Roche’s Julie Warner joins Boyds

She takes up appointment as an associate director at the drug development consultancy

Roche - Basel

Roche moves eye drug lampalizumab into phase III

It could be the first treatment for geographic atrophy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links